Meningococcal disease refers to the bacterial infections causing meningitis and sepsis that can lead to serious illness or even death, if not promptly treated. Rising prevalence of these invasive meningococcal diseases along with growing awareness about the availability of effective vaccines against such infections can boost demand for meningococcal vaccines globally. Furthermore, ongoing research & development activities for new conjugate vaccines against additional serotypes and expanding vaccination programs worldwide can offer numerous opportunities for market players in the near future. However, factors such as high costs associated with vaccine development and threats of substitutes can hamper the market growth.

Market Dynamics:

Global meningococcal vaccines market growth is driven by rising prevalence of invasive meningococcal diseases worldwide due to changing demographics and lifestyle patterns. According to the World Health Organization (WHO), approximately 1.2 million cases of meningococcal meningitis occur every year across the globe, leading to around 135,000 deaths. Growing initiatives by governments and health agencies to promote immunization programs against major serotypes through national vaccination schedules boosts uptake of meningococcal vaccines. Introduction of newer generation multivalent meningococcal vaccines providing protection against additional serogroups can offer opportunities for market players. However, high research and development costs associated with development of novel meningococcal vaccines along with availability of alternative treatment options can hamper the market growth.

Key Features of the Study:

• This report provides in-depth analysis of the global meningococcal vaccines market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global meningococcal vaccines market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include GlaxoSmithKline plc, Sanofi SA, Pfizer Inc., Merck & Co., Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global meningococcal vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global meningococcal vaccines market

Detailed Segmentation-

• By Type
  
  • Polysaccharide Vaccines
  • Conjugate Vaccines
  • Combination Vaccines
  • Other  
    
• By Sales Channel
  
  • Public
  • Private
    
• By Age Group
  
  • Infants (0 to 2 years)
  • Children and Adults (2 years & above)
• By Region:         
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Sanofi Pasteur
  • Merck & Co., Inc.
  • Serum Institute of India Pvt. Ltd.
  • Walvax Biotechnology Co., Ltd.
  • Hualan Biological Engineering Inc.
  • JN-International Medical Corporation
  • Beijing Minhai Biotechnology Co., Ltd
  • Bio-Manguinhos/Fiocruz
  • Chongqing Zhifei Biological Products Co., Ltd.
  • Baxter International
  • CSL Limited
  • Bavarian Nordic
  • Incepta Vaccine Ltd.
  • Sinovac Biotech Ltd.
  • Novartis
  • Panacea Biotec Ltd